PPARG and idiopathic pulmonary fibrosis: While PPARγ agonists have shown limited clinical success in IPF [38], SGZ’s dual PPARα/γ agonism may synergistically enhance lipid metabolic regulation and inflammasome suppression, offering a strategic advantage over single-target agents.